FIELD: chemistry.
SUBSTANCE: invention relates to polymorphs, namely to polymorph 2-acetyl-4H,9H-naphto [2,3-b]furane-4,9-dione, characterised by X-ray diffraction pattern, in fact similar to the one on fig.2, and polymorph of 2-acetyl-4H,9H-naphto [2,3-b]furane-4,9-dione, characterised by X-ray diffraction pattern, in fact similar to the one, given on fig. 3, naphthofurane compounds in form of particles, pharmaceutical compositions for treating cancer, containing one or several naphthofurane compounds, purified compositions for treating cancer, containing one or several said naphthofurane polymorphs in form of particles, methods for obtaining said naphthofurane polymorphs, method for treating cancer in subjects requiring it and method for prolongation of progression-free survival (PFS) in patient with cancer with application of said naphthofurane compounds.
EFFECT: increased efficiency of application of compounds.
36 cl, 25 dwg, 12 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL METHODS FOR TARGETING CANCER STEM CELLS | 2011 |
|
RU2657750C1 |
| NOVEL METHODS FOR TARGETING CANCER STEM CELLS | 2011 |
|
RU2591823C2 |
| PURIFIED PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE COMPOSITIONS AND METHODS OF OBTAINING AND APPLICATION THEREOF | 2010 |
|
RU2556205C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| TOPOTECAN MONOHYDROCHLORIDE PENTAHYDRATE IN CRYSTALLINE FORM, CORRESPONDING COMPOSITIONS BASED ON THEM, PREPARATION AND/OR TREATMENT METHODS | 2004 |
|
RU2352572C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| CRYSTALLINE FORM OF MALEATE OF CONDENSED PYRIDINE DERIVATIVE AND METHODS FOR USE THEREOF | 2016 |
|
RU2712280C2 |
| CRYSTALLINE AND SALT FORMS OF THE TGF-βR1 INHIBITOR AND THE METHOD OF OBTAINING THEM | 2018 |
|
RU2750702C1 |
